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Abstract 
Background: The Plasmodium falciparum histidine-rich protein II (PfHRP2) is a common biomarker used in malaria 
rapid diagnostic tests (RDTs), but can persist in the blood for up to 40 days following curative treatment. The persis-
tence of PfHRP2 presents a false positive limitation to diagnostic interpretation. However, the in vivo dynamics and 
compartmentalization underlying PfHRP2 persistence have not been fully characterized in the plasma and erythro-
cyte (RBC) fraction of the whole blood.
Methods: The kinetics and persistence of PfHRP2 in the plasma and RBC fractions of the whole blood were investi-
gated post-treatment in human clinical samples and samples isolated from BALB/c mice infected with a novel trans-
genic Plasmodium berghei parasite engineered to express PfHRP2 (PbPfHRP2).
Results: PfHRP2 levels in human RBCs were consistently 20–40 times greater than plasma levels, even post-parasite 
clearance. PfHRP2 positive, DNA negative, once-infected RBCs were identified in patients that comprised 0.1–1% 
of total RBCs for 6 and 12 days post-treatment, even post-atovaquone–proguanil regimens. Transgenic PbPfHRP2 
parasites in BALB/c mice produced and exported tgPfHRP2 to the RBC cytosol similar to P. falciparum. As in humans, 
tgPfHRP2 levels were found to be approximately 20-fold higher within the RBC fraction than the plasma post-treat-
ment. RBC localized tgPfHRP2 persisted longer than tgPfHRP2 in the plasma after curative treatment. tgPfHRP2 posi-
tive, but DNA negative once-infected RBCs were also detected in mouse peripheral blood for 7–9 days after curative 
treatment.
Conclusions: The data suggest that persistence of PfHRP2 is due to slower clearance of protein from the RBC fraction 
of the whole blood. This appears to be a result of the presence PfHRP2 in previously infected, pitted cells, as opposed 
to PfHRP2 binding naïve RBCs in circulation post-treatment. The results thus confirm that the extended duration of 
RDT positivity after parasite clearance is likely due to pitted, once-infected RBCs that remain positive for PfHRP2.
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Background
As of 2017, there were over 200 million malaria cases and 
435,000 deaths [1]. Greater than 90% of these malaria 
infections were caused by the Plasmodium falciparum 
parasite predominately in Africa, which causes the most 
severe disease in humans [1]. In Africa, most malaria 
rapid diagnostic tests (RDT) detect the abundant P. fal-
ciparum protein, histidine-rich protein II (PfHRP2) 
[2–4]. Other RDTs detect aldolase or lactate dehydroge-
nase either alone or in combination. At parasite densities 
greater than 500–1000 parasites/µL of whole blood, the 
RDT has demonstrated high sensitivity and specificity, 
similar to the microscopy standard [3–6]. Additionally, 
the low cost, minimal resources required, rapid results, 
and ease of use, has led the World Health Organization 
to recommend the RDT for diagnosing malaria prior to 
treatment in the field [7].
Despite the use of PfHRP2 as the antigen in the RDT, 
PfHRP2 compartmental kinetics in the two blood frac-
tions during infection and during parasite clearance post-
treatment have not been extensively characterized. In 
particular, the dynamics of PfHRP2 in the RBC fraction 
of the whole blood has not been specifically measured. 
To date, the half-life of PfHRP2 has been estimated to be 
3.67 days in plasma and 3–5 days in the whole blood fol-
lowing treatment [8, 9]. Ndour et  al. also demonstrated 
that overall PfHRP2 levels in whole blood treatment 
decreased at a slower rate compared to PfHRP2 plasma 
levels when compared only on day 0 and 3 post-treat-
ment [10]. However, no estimations were specifically 
determined for PfHRP2 clearance time from the RBC 
fraction of the whole blood after treatment for compari-
son, nor were these kinetic parameters in the two dif-
ferent blood fractions (plasma vs. RBCs) compared to 
the clearance time of parasite genomic DNA. Addition-
ally, PfHRP2 demonstrates a unique biologic persistence 
in patients regardless of successful treatment with anti-
malarials, indicating that PfHRP2 clears from the blood 
slower than parasites [10–13]. In fact, PfHRP2 can persist 
at low, detectable levels for several weeks after treatment 
[10–13], presenting a challenge for RDT interpretation 
as a result of false positive interpretations of test results, 
especially when utilizing these tests in malaria endemic 
regions or to measure treatment response and assess 
treatment failure [14].
Plasmodium falciparum is the only human Plasmo-
dium species that produces PfHRP2 with expression 
throughout the asexual intraerythrocytic cycle and early 
stages of gametocytogenesis [15–21]. Each parasite pro-
duces approximately 2–10 femtograms of PfHRP2 per 
48  h replication cycle [20, 21], but only 3% of PfHRP2 
produced is retained by the parasite, localizing to the par-
asite cytoplasm or food vacuole [22, 23]. The remaining 
97% is exported into the infected RBC (iRBC) cytoplasm, 
concentrating in packets near the iRBC membrane [16, 
22]. PfHRP2 can also be secreted from intact iRBCs, but 
the majority (> 90%) is released when mature schizonts 
rupture the iRBC to release merozoites [16, 19]. Follow-
ing release, PfHRP2 can be detected in various bodily flu-
ids including whole blood, RBCs, plasma, serum, urine, 
cerebral spinal fluid, and saliva [16, 19, 24–27]. However, 
the physiological function of PfHRP2 and the significance 
of its localization are unknown. Experimental evidence 
indicates PfHRP2 can promote coagulation [28], interfere 
with immune cell activation [29], and may contribute to 
cerebral malaria pathology by disrupting barrier integrity 
in the brain [30].
To probe PfHRP2 kinetics in vivo, human whole blood 
samples were fractionated into their component parts of 
plasma and washed RBCs for PfHRP2 quantification and 
immunofluorescence analysis. A novel transgenic Plas-
modium berghei mouse parasite was also engineered to 
express the PfHRP2 protein (PbPfHRP2) for an additional 
in  vivo model for further correlative studies of PfHRP2 
kinetics.
Methods
Plasmodium falciparum patient blood collection
De-identified, human whole blood samples isolated from 
patients with a P. falciparum infection were collected 
from the Johns Hopkins Hospital Microbiology Lab. 
DNA was extracted from 20 µL of whole blood using 
the QIAamp DNA Blood Mini Kit and eluted in 50 µL 
of water for qPCR amplification, as described previously 
[31], using novel oligonucleotide primers and a fluo-
rescent probe specific for the P. falciparum Pfs25 gene 
(Additional file  1: Table  S1). The remaining blood was 
centrifuged at 5000×g for 4.5 min to separate plasma and 
RBC fractions. The RBCs were washed four times with 
1 mL of PBS.
Recombinant and native PfHRP2 protein purification
The PfHRP2 gene, inserted into the pET 15b vector 
and cloned into Escherichia coli BL 21/DE3 cells, was 
expressed and purified using a previously described pro-
tocol [23]. Native PfHRP2 protein was purified using 
the same protocol from pelleted RBCs cultured with the 
P. falciparum FCQ79 parasite strain provided by PATH 
[23]. Concentrations of purified proteins were deter-
mined using amino acid analysis completed by the Pro-
tein Structure Core at the University of Nebraska.
Construction of transgenic PbPfHRP2 parasite
The full-length P. falciparum 3D7 HRP2 
(PF3D7_0831800) gene was inserted into the pL1694 vec-
tor and expressed under the P. berghei HSP70 promoter, 
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with a 2A skip peptide between PfHRP2 and GFP. The 
cassette was flanked with integration sites for the 230p 
gene in P. berghei. Second passage P. berghei (strain 
ANKA) parasites were purified from 5 mice at 1% para-
sitaemia by collecting blood via cardiac puncture. Puri-
fied, mature schizonts (5 × 107) were generated in  vitro 
and transfected with 10  µg of pL1694 + HRPII-2A-GFP 
linearized with Bcl1 and Sap1, as previously described 
[32, 33]. Transfected parasites were injected into the 
tail vein of 6–8-week-old female Swiss Webster mice 
(Taconic). Utilizing the human dihydrofolate reductase 
(DHFR) selection cassette, progeny were selected with 
pyrimethamine at 7 mg/mL in the drinking water. Blood 
was collected via cardiac puncture and single clones of 
transfected parasites were generated by diluting para-
sites at 1 parasite/mouse across 20 mice. Isolated clones 
were screened by PCR for correct genetic manipulation 
(Additional file 2). PfHRP2 protein expression in vivo was 
verified by RDT, western blot, and immunofluorescence 
microscopy (Fig. 3).
In vivo murine model for measuring transgenic PfHRP2 
kinetics
Eleven 8-week-old female BALB/c mice (Jackson Labo-
ratory) were infected with approximately 500,000 to 
1,000,000 PbPfHRP2 iRBCs isolated from a donor mouse. 
Once mice reached > 5% parasitaemia at days 4–5 post-
infection, they were administered, via intraperitoneal 
injection, 3 doses of 50 mg/kg of artesunate at 0, 8, and 
24  h and a single dose of 36  mg/kg of pyronaridine at 
24  h. Artesunate (Sigma-Aldrich) was dissolved in 5% 
 NaHCO3 and pyronaridine tetraphosphate (Sigma-
Aldrich) was dissolved in nuclease-free water. Para-
site clearance time was monitored by blood films and 
qPCR performed as previously described [31] on DNA 
extracted from 20 µL of whole blood, using primers and 
probes specific for P. berghei ANKA 18S rRNA (Addi-
tional file  1: Table  S1). Three copies of 18S rRNA/para-
site was assumed to calculate parasites/µL because the 
primers and probes are capable of binding 3 copies of the 
P. berghei 18S rRNA gene on chromosomes 5, 7 and 12, 
as was determined by BLASTing the sequences of these 
primers and probes against the P. berghei ANKA genome 
using PlasmoDB v.41. In the P. berghei genome, there are 
four ribosomal units, classified into two types, A-type 
(includes units A and B) and S-type (includes units C and 
D) [34], and three of these four units have been shown to 
have greater than 90% sequence homology (A, C, and D) 
[34–36]. 140 µL of tail blood was drawn daily for protein 
quantification. Drawing this volume of blood daily did 
not impact protein kinetics or clearance, as blood drawn 
only prior to treatment (day 0) and on day 5 or 7 post-
treatment yielded similar PfHRP2 kinetics.
The blood was centrifuged at 5000×g for 4.5  min to 
separate plasma and RBC fractions. The RBCs were 
washed four times with 1 mL of PBS. The same methods 
were used for the splenic and asplenic mouse experi-
ments. Female BALB/c mice (n = 5) were splenectomized 
by a Johns Hopkins veterinarian at 7  weeks of age, 
2 weeks prior to infection.
Immunofluorescence microscopy
Slides were fixed and permeabilized in methanol at 
− 20 °C for 20 min and stored at − 80 °C. Prior to stain-
ing, slides were blocked for 1  h at room temperature 
with 1% bovine serum albumin (BSA)/PBS. Slides were 
washed with PBS and incubated for 1 h with mouse anti-
PfHRP2 antibody 3A4 (1  mg/mL) conjugated to Alexa 
Fluor-594 diluted 1:200 in 1% BSA/PBS. After washing, 
slides were incubated with a rabbit anti-Plasmodium 
enolase antibody diluted 1:50 in 1% BSA/PBS. Slides 
were washed and incubated for 1  h with Alexa Fluor-
488 labeled goat anti-rabbit IgG (Invitrogen), diluted 
1:500 in 1% BSA/PBS. Slides were washed and briefly 
dried. ProLong Gold antifade reagent with DAPI (Ther-
moFisher) was added to the wells and sealed under a 
coverslip. Images were captured with the Zeiss AxioIm-
ager M2 microscope equipped with a Hamamatsu Orca 
R2 camera. Deconvolution and image analysis were done 
using the Velocity Imaging Software. Approximately 1500 
RBCs were counted for each human patient (n = 6) to 
determine the percentage of PfHRP2 positive, DAPI neg-
ative, once-infected RBCs.
PfHRP2 enzyme‑linked immunosorbent assay (ELISA)
The Malaria Ag CELISA specific for PfHRP2 used to 
quantify PfHRP2 in murine and patient samples was per-
formed according to the manufacturer’s instructions [37]. 
Absorbance was read at 450 nm using the BMG Labtech 
POLARstar OPTIMA plate reader. The limit of detec-
tion (LOD) was determined on each plate by averaging 
the absorbance of the negative controls for each blood 
fraction and adding 3 standard deviations to the mean. 
Any absorbance reading under the LOD was defined as 
PfHRP2 negative. The limit of quantitation (LOQ) was 
determined by the linear range of the standard curve 
on each plate. The LOQ was approximately 2  ng/mL of 
PfHRP2.
PfHRP2 RBC binding assay
Plasma isolated from P. falciparum-infected patients 
(n = 5) at a concentration of 1000–3000  ng/mL of 
PfHRP2, and human serum spiked with a very high con-
centration of rPfHPR2 well above circulating plasma 
levels observed during severe infection, or a lower con-
centration of PfHRP2, were added to uninfected, human 
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 O+ erythrocytes to reconstitute whole blood at a 40% 
haematocrit. Additionally, 200 µL of tail blood was drawn 
from naïve BALB/c mice and deposited in 20 µL of 1 mg/
mL heparin in PBS. Blood was centrifuged at 5000×g 
for 4.5  min to isolate plasma. The RBCs were washed 
one time with 1 mL of PBS. The mouse plasma was then 
spiked with the same concentrations of rPfHRP2 and 
added to the washed RBCs to reconstitute whole blood 
at 40% haematocrit. Plasma/sera samples containing no 
PfHRP2 protein were used as controls. All were incu-
bated at 37 °C for at least 12 h. After incubation, samples 
were centrifuged to separate plasma from RBCs. RBCs 
were subsequently washed 4 times with 1  mL of PBS. 
Three individual replicates were performed.
In vivo model for measuring recombinant PfHPR2 plasma 
kinetics
Naïve, 8-week old female BALB/c mice received an intra-
peritoneal injection of 20  µg of recombinant PfHRP2 
(rPfHRP2) in 200  µL of PBS. Tail blood (50 or 100 µL) 
was deposited in 1  mg/mL heparin in PBS to prevent 
clotting. Blood was centrifuged at 5000×g for 4.5 min to 
isolate plasma. The remaining RBCs were washed two 
times with 1 mL of PBS.
Data analysis
The majority of data was analysed using GraphPad Prism 
(v.5). Data are graphed as mean ± SEM. PfHRP2 levels in 
the RBCs and plasma were extrapolated using a standard 
curve and linear regression analysis. Protein half-life was 
determined using a first-order decay equation. For the 
comparison between splenic and asplenic mice, data were 
normalized to percent of total remaining. The statisti-
cal methods used include: the Wilcoxon signed-rank test 
or Mann–Whitney U test to measure differences in the 
means of two matched or unmatched groups, first-order 
decay analysis to calculate half-life, log-rank survival 
analysis to compare clearance times, and a random-
effects GLS regression model for analysing associations 
between tgPfHRP2 in the plasma and RBC fractions of 
splenic or asplenic mice. The random-effects GLS regres-
sion was used to account and adjust for within-subject 
correlation, using random intercept and robust standard 
errors. This analysis was performed with Stata version 14 
(StataCorp LP, College Station, USA).
Results
Persistence of PfHRP2 within human RBCs
The persistence of PfHRP2 in whole blood has been doc-
umented [10–13], but has not been extensively character-
ized in the blood’s individual compartments, the plasma 
and the RBCs. We obtained whole blood from 6 patients 
diagnosed with P. falciparum malaria at the hospital lab-
oratory with parasitaemias ranging from < 0.5 to 12%, as 
measured by microscopy (Table 1). The whole blood was 
fractionated into plasma and washed RBCs for a quantita-
tive, compartmental analysis of PfHRP2 by ELISA before 
and after treatment with anti-malarial combinations of 


















1 1 482,693 183,208 7116 26 11.6 Not done Doxycycline, quinidine, 
artemether–lumefantrine2 2759 160,177 2289 70 < 0.5 3.7
2.4 502 74,179 2272 33 0 5.2
3 150 79,094 1214 65 0 6.5
12 0 25,830 397 65 0 3.5
2 1 11,945 37,948 1999 19 1.2 Not done Atovaquone–proguanil
3 516 4535 92 49 < 0.5 0.38
3 0 50,398 43,787 2113 21 2.8 0 Artemether–lumefantrine
1 498 16,370 1529 11 0 1.2
2 158 8821 847 10 0 0.63
4 1 14,289 21,140 85 248 1.0 Not done Quinine, atovaquone–proguanil
6 0 43 21 2 0 1.7
5 0 24 277 11 25 < 0.5 Not done Atovaquone–proguanil
1 12,863 38,051 3 12,683 1.1 Not done
3 101 2759 129 21 0 0
6 2 3141 12,372 181 68 < 0.5 0.13 Atovaquone–proguanil
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artemether–lumefantrine (n = 2) or atovaquone–progua-
nil (n = 4) (Table 1; Fig. 1a, b). The initial ratio of RBC to 
plasma levels of PfHRP2 prior to treatment approximated 
20-fold and this ratio tended to increase to 40-fold or 
greater following treatment with both anti-malarial regi-
mens (Table  1; Fig.  1c). PfHRP2 levels in the RBC frac-
tion only declined three-to tenfold in the days following 
either treatment regimen, while genomic copies of the P. 
falciparum Pfs25 gene decreased 20- to 100-fold (Table 1; 
Fig. 1a, b). All iRBCs cleared from the peripheral blood 
within 2–3  days post-treatment when measured by 
microscopy, despite parasite genomic DNA remaining 
detectable when measured by qPCR (Table 1). To identify 
the source of PfHRP2 in the blood post-parasite clear-
ance, we performed immunofluorescence microscopy 
on RBCs with an antibody specific for PfHRP2 and DAPI 
staining to identify parasites. Remarkably, we observed 
PfHRP2 positive, but DNA negative, RBCs at approxi-
mately 0.1–1% of total RBCs post-treatment, specifically 
from days 1 to 3 and day 12 post-treatment (Table  1; 
Fig.  2; Additional file  3). This indicated the presence of 
what was likely once-infected RBCs, in which the parasite 
was cleared, but PfHRP2 remains within the cytoplasm of 
the RBC. The phenomenon was observed after treatment 
with both artemether–lumefantrine and atovaquone–
proguanil in the small number of patients we examined 
(Table 1; Fig. 2). Also, in the 6 patients tested, no once-
infected RBCs were observed pre-treatment (Additional 
file 4).
Transgenic PbPfHRP2 parasites synthesize and export 
the PfHRP2 protein
In order to fine tune the dynamics of PfHRP2 in vivo, a 
controlled experimental model was utilized in which a 
P. berghei rodent parasite (PbPfHRP2), which lacks the 
PfHRP2 gene family, was engineered to express PfHRP2 
(tgPfHRP2) (Additional file  2). Expression and localiza-
tion of the transgenic PfHRP2 protein (tgPfHRP2) was 
validated in the novel mouse model by western blot 
and immunofluorescence (Fig.  3). The presence of tgP-
fHRP2 in the whole blood of BALB/c mice was detected 
using a BinaxNOW Malaria Rapid Diagnostic Test™ 
that qualitatively detects PfHRP2 and pan-species aldo-
lase (Fig. 3a). Western blot analysis confirmed the pres-
ence of tgPfHRP2 in the iRBCs (Fig. 3b). tgPfHRP2 was 
detected in the RBC cytosolic fraction after saponin lysis 
(Fig. 3b), suggesting it was exported into the iRBC cyto-
plasm. Immunofluorescence microscopy on PbPfHRP2 
iRBCs was performed using monoclonal antibodies 
against PfHRP2 and Plasmodium enolase, a known par-
asite-localized protein, to differentiate the parasite from 
the iRBC cytoplasm. In this assay, tgPfHRP2 localized to 
both the parasite and iRBC cytoplasm (Fig.  3c). Impor-
tantly, the PfHRP2 staining observed in PbPfHRP2 iRBCs 
mimicked the staining of P. falciparum iRBCs (Fig.  3c). 
PfHRP2 was not detected in negative controls, including 
RBCs infected with the P. berghei ANKA wild-type strain 
that does not express PfHRP2 and uninfected RBCs 
(Fig. 3b, c).
Investigating kinetics of tgPfHRP2 during infection 
with PbPfHRP2
BALB/c mice were infected with PbPfHRP2 and 5  days 
post-infection, reached an average parasitaemia of 10.5%, 
as measured by microscopy, or 675,283 parasites/µL 
quantified by qPCR (Fig.  4a). On day 5 post-infection, 
Fig. 1 Kinetics of PfHRP2 following P. falciparum infection. a, b 
Blood was drawn from patients and fractionated into plasma and 
RBCs. Parasite genomic DNA clearance in a representative single 
patient post-treatment with artemether–lumefantrine (a, left) or 
atovaquone–proguanil (b, left) was quantified using TaqMan primers 
and probes specific for P. falciparum Pfs25. PfHRP2 protein levels were 
quantified in the plasma and RBCs post-treatment with artemether–
lumefantrine (a, right) and atovaquone–proguanil (b, right) by ELISA. 
c The ratio of PfHRP2 concentration in the RBCs to plasma in each 
patient (n = 6) was calculated over the days post-treatment. Data are 
represented as mean ± SEM
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mice were treated with three doses of 50 mg/kg of artesu-
nate (0–8–24  h post-initial treatment) and 36  mg/kg of 
pyronaridine (24  h post-initial treatment) to cure mice 
of parasites (Fig.  4a). At this peak parasitaemia prior to 
treatment, the average concentrations of tgPfHP2 in the 
plasma and RBCs were 12,512  ng/mL and 179,433  ng/
mL, respectively (Fig. 4a, b). tgPfHRP2 levels were signifi-
cantly higher in the RBC fraction (10–20 fold) compared 
to the plasma over the days post-treatment (p ≤ 0.0001, 
random-effects GLS regression model) (Fig.  4b, c). The 
Fig. 2 Presence of once-infected RBCs post-treatment with different anti-malarials. Once-infected RBCs were detected in patients on day 3 
post-treatment with either artemether–lumefantrine (left) or atovaquone–proguanil (right). Once-infected RBCs were defined as cells with positive 
PfHRP2 staining (red) but no DAPI staining (blue)
Page 7 of 15Poti et al. Malar J           (2019) 18:78 
half-life of tgPfHRP2 following treatment was calculated 
for each blood fraction using a first-order decay equation. 
While not significantly different, tgPfHRP2 had a slightly 
longer half-life in the RBCs at 13.1 h (median  R2 = 0.989) 
compared to 10.2  h in the plasma (median  R2 = 0.999) 
(p = 0.27, Wilcoxon signed-rank test) (Fig. 4d).
Determining tgPfHRP2 persistence duration in the plasma 
and RBCs compared to microscopy and PCR
Median parasite clearance time measured by microscopy 
was 3 days post-treatment (Fig. 5a). However, the median 
parasite genomic DNA clearance time quantified by 
qPCR was significantly longer at 7 days (p  ≤ 0.0001, log-
rank) (Fig. 5a). Median plasma tgPfHRP2 clearance time 
was 5 days while RBC clearance was significantly longer 
at 9 days (p ≤ 0.0001, log-rank) (Fig. 5b). Consequently, 
tgPfHRP2 positivity in the different blood fractions, 
particularly within the RBC fraction, outlasted detectable 
parasites by microscopy (Fig.  5a, b). Parasite genomic 
DNA was detected by qPCR longer than plasma tgP-
fHRP2, but protein in the RBCs persisted at least 1-day 
post genomic DNA clearance (Fig.  5a, b). tgPfHRP2 
clearance time from the RBCs measured by ELISA cor-
related with its clearance time from whole blood of 
8–9 days measured by RDT (Fig. 5c). RDT analysis also 
demonstrated that the Plasmodium aldolase protein was 
eliminated from the whole blood on day 4 post-treat-
ment, shortly after parasites were no longer detected in 
peripheral blood (Fig. 5c).
Identifying once‑infected, tgPfHRP2 positive murine RBCs 
post‑treatment
The source of tgPfHRP2 in RBCs after parasite clearance 
was hypothesized to be once-infected RBCs, positive 
Fig. 3 Characterization of the synthesis and localization of PfHRP2 by transgenic PbPfHRP2 parasite. a BinaxNOW Malaria RDT™ detecting tgPfHRP2 
and Plasmodium aldolase in the whole blood of a PbPfHRP2 infected mouse. b tgPfHRP2 was detected in iRBCs, and exported to the iRBC cytoplasm 
(Saponin, SN). RBCs were lysed with saponin to isolate their cytoplasmic fraction. Purified recombinant and native PfHRP2 protein were run as 
controls. c tgPfHRP2 (red) localized within the parasite, demarcated by Plasmodium enolase staining (green), and the RBC cytosol, similar to what 
was observed in P. falciparum iRBCs. An uninfected mouse RBC and a P. berghei ANKA iRBC that does not produce PfHRP2 are shown as controls
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for PfHRP2 but parasite negative, as were observed in 
human patients post-treatment (Fig.  2). Immunofluo-
rescence microscopy on mouse RBCs was performed 
with an antibody specific for PfHRP2 and DAPI staining 
to identify parasites. tgPfHRP2 was detected in iRBCs 
(DAPI positive) isolated pre-treatment as well as in 
RBCs isolated 2, 3, and 4 days post-treatment that were 
DAPI negative (Fig.  6a). This indicates the presence of 
once-infected RBCs positive for PfHRP2 in their cyto-
plasm in our mouse model. Importantly, PfHRP2 was 
not detected in naive mouse or human RBCs, indicating 
specific recognition of parasite derived PfHRP2 (Fig. 6). 
PfHRP2-positive, parasite-negative, once-infected RBCs 
that were observed in a human patient on days 2, 3 and 
12 post-treatment with artemether–lumefantrine for a P. 
falciparum infection with an 11.6% initial parasitaemia 
(Fig. 6b), were morphologically similar to those identified 
in the mouse model (Fig. 6).
Investigating potential binding of PfHRP2 to uninfected, 
naïve RBCs
Slower clearance of PfHRP2 from the RBC fraction in 
humans and mice could be the result of plasma PfHRP2 
binding to naïve RBCs in circulation. To investigate bind-
ing, partitioning of PfHRP2 was measured between naïve 
RBCs and plasma isolated from P. falciparum infected 
patients or human serum/mouse plasma spiked with 
recombinant PfHRP2 at average levels > 100,000  ng/
mL or < 30,000 ng/mL as measured by ELISA, that were 
incubated together in vitro (Additional file 5: Table S2). 
Fig. 4 Kinetics of tgPfHRP2 following PbPfHRP2 infection. Tail blood was extracted daily from PbPfHRP2 infected female BALB/c mice 
post-treatment with artesunate and pyronaridine administered for cure (n = 11). Blood was fractionated into plasma and RBCs. a Parasite genomic 
DNA clearance post-treatment was quantified using qPCR, with TaqMan primers and probes specific for P. berghei ANKA 18S rRNA. Data are 
represented as mean ± SEM. b tgPfHRP2 protein levels post-treatment were quantified in the two blood fractions by ELISA. Data are represented as 
mean ± SEM. c The ratio of tgPfHRP2 concentration in the RBCs to plasma in each mouse was calculated over the first 4 days post-treatment. Data 
are represented as mean ± SEM. d The half-life of the tgPfHRP2 was quantified in the plasma and washed RBCs using a first-order decay equation 
model constrained at a plateau of Y = 0. Each point represents an individual mouse with mean ± SEM displayed. Data were analysed using a 
Wilcoxon signed-rank test
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Binding was defined as absorbance levels above those 
measured for RBCs incubated with naïve plasma. While 
protein levels quantified by ELISA were highly variable 
in the RBC and plasma fractions within and across repli-
cates, the average percent of total PfHRP2 protein bound 
to uninfected, naïve mouse or human RBCs in vitro was 
extremely low, measuring below 0.5% for all plasma/
serum samples tested (Additional file 5: Table S2).
Next, binding was investigated in  vivo. BALB/c mice 
(n = 3) were injected with 100,000  ng/mL of recombi-
nant PfHRP2 (rPfHRP2) in order to achieve high plasma 
protein levels and mimic plasma protein circulation and 
elimination observed during severe malaria infections 
(> 10% parasitaemia) [20, 27, 38]. ELISA was used to 
quantify concentration and partitioning of rPfHRP2 in 
the RBC and plasma fractions isolated from mice at regu-
lar intervals post-inoculation (Additional file 6: Table S3, 
Additional file 7). At 0.5 h post-inoculation, the average 
concentration of rPfHRP2 quantified in the plasma was 
35,113 ng/mL (Additional file 7).
Minimal binding to uninfected RBCs was detected 
within the first 12  h post-inoculation, on the order 
of 3–13  ng/mL compared to the 900–35,000  ng/mL 
of rPfHRP2 in the plasma at those same time points 
(Additional file  6: Table  S3). Consequently, the ratios 
of rPfHRP2 in the uninfected RBCs compared to the 
plasma in the first 12  h were extremely low, averaging 
0.004 (Additional file 6: Table S3). The percent of the total 
protein (RBC + plasma) that bound to the RBCs over 
the time course was ≤ 1% (Additional file  6: Table  S3). 
No binding was detected in the naïve RBCs after 24  h, 
despite plasma protein remaining detectable for a median 
of 4  days post-inoculation (Additional file  7; Additional 
file  6: Table  S3). rPfHRP2 plasma clearance followed a 
first-order decay process, with a very short calculated 
plasma half-life of 1.9 h (median  R2 = 0.998) (Additional 
file 7).
Comparing parasite and tgPfHRP2 clearance in splenic 
and asplenic mice
Because RBC pitting occurs in the spleen, how sple-
nectomy in mice alters clearance, persistence, and 
kinetics of tgPfHRP2 following infection with the PbP-
fHRP2 parasite and treatment with artesunate and 
pyronaridine was investigated. The parasitaemia prior 
to treatment (4–5  days post-infection) determined by 
qPCR was significantly different between the splenic 
(675,283 parasites/µL) and asplenic (1,429,170 para-
sites/µL) mice (Mann–Whitney U test, p = 0.041). To 
normalize the data, the percent of total parasite DNA 
remaining was calculated (Fig.  7a). On average, 71% 
of total parasite DNA cleared on day 1 post-treatment 
Fig. 5 Clearance times of PbPfHRP2 parasites and tgPfHRP2 protein. Female BALB/c mice infected with the PbPfHRP2 parasite (n = 11) were 
administered artesunate and pyronaridine to cure. a Parasite clearance and cure were determined by daily Giemsa-stained blood films and qPCR 
performed on DNA extracted from whole blood, using TaqMan primers and probes specific for P. berghei ANKA 18S rRNA. b Blood extracted from 
each infected mouse was separated into plasma and RBC fractions to measure the presence and clearance of tgPfHRP2 post-treatment by ELISA. 
Curves were compared using a log-rank test (***p < 0.001; **p < 0.01; *p < 0.05). c Representative BinaxNOW Malaria RDTs demonstrating the 
clearance time of tgPfHRP2 and Plasmodium aldolase from the whole blood of a PbPfHRP2 infected mouse that was administered artesunate and 
pyronaridine to cure
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in splenic mice, but only 49% cleared in asplenic mice 
(Fig.  7a). Additionally, in mice with intact spleens, all 
parasite DNA cleared by day 7 post-treatment, but in 
asplenic mice, DNA was detectable at very low levels 
(≤ 1%) from days 12 to 14 post-treatment, leading to 
a significantly longer overall clearance time of 13 days 
(p = 0.0001, log-rank) (Fig. 7a, b). When measuring par-
asite clearance by microscopy, no differences between 
splenic and asplenic mice were observed, as both dem-
onstrated a median clearance time of 3 days.
In asplenic mice, the concentration of tgPfHRP2 
was significantly higher in the RBCs compared to the 
plasma over the days post-treatment (p = 0.005, ran-
dom-effects GLS regression model) (Fig.  7c), which 
was the same trend observed in splenic mice. tgPfHRP2 
elimination from the different blood fractions post-
treatment also followed a first-order decay process 
in the mice lacking spleens. In the asplenic mice, the 
average tgPfHRP2 plasma half-life was 16.4  h (median 
 R2 = 0.990) and the average half-life in the RBCs was 
not significantly different at 13.4 h (median  R2 = 0.998) 
(p = 1.00, Wilcoxon signed-rank test). The starting 
tgPfHRP2 concentration in the RBC fraction of PbP-
fHRP2 infected mice prior to treatment was higher in 
the splenic group (179,432.6  ng/mL) compared to the 
asplenic group (144,806  ng/mL), despite a lower para-
site load calculated by qPCR. Data was normalized 
to percent of total tgPfHRP2 remaining in the RBCs 
(Fig. 7d). Interestingly, when comparing percent of total 
protein remaining in the RBCs post-treatment for the 
splenic and asplenic mice, the initial tgPfHRP2 clear-
ance rate for more than 99% of the protein was not dif-
ferent within the first 6  days post-treatment (Fig.  7d). 
Consequently, the tgPfHRP2 RBC elimination half-
lives in splenic (13.1 h) and asplenic mice (13.4 h) were 
not significantly different (p = 1.00, Mann–Whitney 
U Test). However, lingering, low levels of tgPfHRP2 
(< 1%) were detected in the RBCs of the asplenic mice 
during days 10–14 post-treatment, leading to a sig-
nificantly longer overall median clearance time of 
13 days (p = 0.0009, log-rank) (Fig. 7d, e). This was not 
observed in the splenic group, which had a median 
clearance time of 9 days. As in splenic mice, tgPfHRP2 
persisted significantly longer in the RBCs (11–14 days) 
than the plasma (6–10 days) in asplenic mice (Fig. 7d). 
One apparent difference between these groups was that 
in asplenic mice, the tgPfHRP2 protein in the RBCs 
cleared at the same time or before parasite genomic 
DNA (Fig.  7b, e). In the splenic mice, at least a 1-day 
difference in clearance time was observed (Fig. 5).
Discussion
Because PfHRP2 is expressed solely by P. falciparum, 
previous experimentation to measure PfHRP2 kinetic 
parameters have relied on in  vitro culture and human 
studies using mostly whole blood and occasionally 
plasma [8–10, 39]. Here the compartmentalization of 
PfHRP2 in the blood was explored in limited human 
clinical samples and correlated some of the findings 
in a novel transgenic P. berghei parasite (PbPfHRP2) 
engineered to express PfHRP2 under the control of the 
HSP70 promoter. Consistently higher levels of PfHRP2 
in the RBC fraction compared to the plasma was demon-
strated over the days post-treatment in both humans and 
the transgenic PbPfHRP2 mouse model, which is consist-
ent with data that previously demonstrated lower plasma 
PfHRP2 levels compared to overall levels in the whole 
blood post-treatment [10].
Fig. 6 Investigation of PfHRP2 persistence in once-infected 
RBCs post-treatment. a PbPfHRP2 iRBCs were isolated from mice 
pre-treatment and once-infected RBCs were isolated on days 2, 3, 
and 4 post-treatment with artesunate and pyronaridine. Uninfected 
mouse RBCs were used as a control. b P. falciparum iRBCs were 
collected from a patient pre-treatment. RBCs once-infected with P. 
falciparum were isolated from the same human patient on days 2, 3, 
and 12 post-treatment with artemether–lumefantrine. Uninfected 
human RBCs were used as a control. Once-infected RBCs were 
defined as cells with positive PfHRP2 staining (red) but no DAPI 
staining (blue)
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There is recent evidence that persistence of the PfHRP2 
antigen is due to the clearance of dying and non-viable 
parasites by the process of erythrocyte pitting in the 
spleen, in which the parasite is removed by splenic 
macrophages from an intact RBC that then returns 
to circulation as a once-infected RBC [10, 40]. These 
once-infected RBCs have been identified and quanti-
fied previously by the presence of the P. falciparum 
ring-infected erythrocyte surface antigen (RESA) using 
flow cytometry and immunofluorescence microscopy 
[10, 41]. RESA, like PfHRP2, is exported into the cyto-
plasm of the iRBC and associates with the iRBC mem-
brane [42]. Recently, Ndour et al. also identified PfHRP2 
in these once-infected RBCs isolated from P. falcipa-
rum patients 3  days post-artesunate treatment [10]. If 
PfHRP2 is persisting within circulating once-infected 
RBCs, this would predict slower protein clearance from 
the RBC fraction of the blood compared to the plasma. 
This was demonstrated in human patients treated with 
either artemether–lumefantrine or atovaquone–progua-
nil. While the number of patients investigated was small, 
it appears that this pitting phenomenon potentially not 
only results from artesunate treatment and should be 
further investigated in regards to treatment with other 
anti-malarial regimens. In the transgenic mouse model 
post-treatment with artesunate and pyronaridine, tgP-
fHRP2 also cleared more slowly from the RBCs than 
plasma. Once-infected, PfHRP2 positive, parasite nega-
tive RBCs were abundantly detected post-treatment in 
humans (at 0.1–1%) and were also observed in our mouse 
model. The results confirm previous observations [10] 
and suggest that these once-infected RBCs that remain 
PfHRP2 positive and circulate in the peripheral blood 
could be contributing to the long duration of RDT posi-
tivity despite the lack of an active infection. In the mouse 
model, tgPfHRP2 persisted in the RBCs for at least 
5–7 days beyond measurable peripheral blood parasitae-
mia by microscopy. However, tgPfHRP2 only persisted 
Fig. 7 tgPfHRP2 protein kinetics following infection in splenectomized mice. Female BALB/c mice (n = 5) were splenectomized and infected 
with the PbPfHRP2 parasite. Artesunate and pyronaridine were administered for cure. a, b Parasite genomic DNA clearance post-treatment was 
quantified in the splenectomized mice using qPCR, with TaqMan primers and probes specific for P. berghei ANKA 18S rRNA, and compared to 
parasite clearance time in mice with intact spleens (n = 7). Data were normalized by calculating percent of total parasite DNA remaining (a). Overall 
clearance time for parasite DNA was compared in splenic and asplenic mice using a log-rank test (***p < 0.001; **p < 0.01, *p < 0.01) (b). Data are 
represented as mean ± SEM. c Tail blood was extracted daily from splenectomized mice to quantify the concentration of tgPfHRP2 post-treatment 
in the plasma and RBCs by ELISA. Data are represented as mean ± SEM. tgPfHRP2 levels post-treatment in the RBCs of both the splenic and asplenic 
mice were compared. Data were normalized by calculating percent of total tgPfHRP2 remaining (d). Overall clearance time for RBC tgPfHRP2 was 
compared in splenic and asplenic mice using a log-rank test (***p < 0.001; **p < 0.01, *p < 0.01) (e). Data are represented as mean ± SEM
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1  day post parasite genomic DNA clearance time as 
measured by qPCR for the P. berghei ANKA 18S rRNA.
Because erythrocyte pitting is a method of parasite 
removal in the spleen, the impact of splenectomy on the 
in vivo tgPfHRP2 kinetics in the RBCs was investigated. 
The spleen plays a central role in clearing parasites dur-
ing infections with P. falciparum [43–45] and lethal 
rodent malaria strains [46, 47]. It has been demonstrated 
that in asplenic patients post-artesunate, treatment, par-
asite clearance was prolonged, though most parasites 
appeared dead and were unable to be cultured ex  vivo 
[43, 48]. Consequently, the spleen is necessary for para-
site clearance following the rapid anti-malarial activity 
of artemisinin-based compounds [48]. In the transgenic 
mouse model, we observed lingering, low levels of para-
site DNA in the asplenic mice, leading to a longer overall 
median clearance time of 13 days. This could suggest that 
parasite DNA may persist after parasites are killed.
Supporting the hypothesis that erythrocyte pitting 
depends on the spleen, once-infected, RESA positive 
RBCs have not been observed in splenectomized patients 
[43], nor were they observed in  vitro, following artesu-
nate treatment of P. falciparum culture [49]. While the 
clearance of more than 99% of the tgPfHRP2 protein 
from the RBC fraction was similar in splenic and asplenic 
mice, there was a slower clearance of the remaining pro-
tein in asplenic mice. Parasite clearance mechanisms in 
the absence of a spleen have not been extensively char-
acterized, particularly in mice, but the liver along with 
other lymphoid tissues may play a role [46]. One poten-
tial explanation could be that without the spleen to clear 
parasites, slower parasite clearance overall could result in 
prolonged detection of tgPfHRP2 in RBCs.
Additionally, PfHRP2 could be binding uninfected 
RBCs in circulation upon its release from iRBCs, con-
tributing to persistence. Little binding of PfHRP2 to 
naïve RBCs was observed, as the percent of total pro-
tein bound was under 1–0.5% for all conditions tested. 
Transmission electron microscopy images and protein 
localization analysis from a previous study demonstrated 
that PfHRP2 was localizing within the cytoplasm, imme-
diately under the plasma membrane of P. falciparum 
once-infected RBCs, further supporting the results [10]. 
Therefore, it seems binding of PfHRP2 to the surface of 
uninfected RBCs is negligible and consequently not con-
tributing to persistent antigenaemia.
One important difference observed between our novel 
transgenic murine model and P. falciparum infection in 
humans is the duration of PfHRP2 persistence after treat-
ment. In mice infected with the transgenic PbPfHRP2, we 
measured persistent antigenaemia for only 8–9 days fol-
lowing treatment, where PfHRP2 has been detected up 
to 28–40 days following P. falciparum infections [11–13] 
and once-infected, PfHRP2 positive RBCs were observed 
as long as 12  days post-treatment in our small human 
study. These pitted, once-infected P. falciparum RBCs 
have a shorter lifespan (7–28 days) than a naïve human 
RBC (100–120  days) [10, 41]. Naïve murine RBCs only 
have a lifespan of approximately 30–40 days [50, 51]. As 
a result, pitted murine once-infected PbPfHRP2 RBCs 
could have a shorter lifespan of only a few days, causing 
shorter persistence duration. Additionally, shorter per-
sistence duration could be due in part to the increased 
pliability of P. berghei iRBCs [52], as erythrocyte pitting 
seems to correlate with the increased rigidity of P. falci-
parum iRBCs [53]. Also unlike P. falciparum, P. berghei 
preferentially infects reticulocytes [54], which differ from 
mature RBCs and may not undergo pitting. The splenic 
architecture of mice and humans differs [55–57], but 
the ability of murine spleens to mechanically trap RBCs 
with foreign/inclusion bodies and remove them through 
a pitting-like mechanism has been demonstrated previ-
ously [58]. In fact, the number of Howell-Jolly inclusion 
bodies increased from 2 to 3% in the peripheral blood of 
mice following splenectomy [59]. Therefore, it is possi-
ble that the trapping and pitting mechanisms employed 
in the mouse spleen are different from those in humans 
and may be less sophisticated, leading to less pitting and 
a shorter duration of PfHRP2 persistence in mice com-
pared to humans. This could also explain the similar 
kinetics observed for tgPfHRP2 post-treatment in the 
RBC fractions of splenic and asplenic mice.
Conclusions
PfHRP2 persistence after treatment presents a criti-
cal challenge to diagnostic interpretation of the malaria 
RDT, but the mechanism underlying this phenomenon 
has not been extensively characterized. In this study, a 
transgenic P. berghei parasite that expresses PfHRP2 was 
generated and tgPfHRP2 kinetics was investigated in the 
plasma and RBC fractions of the whole blood over time 
post-treatment to correlate with human samples. Persis-
tent PfHRP2 antigenaemia was observed for 8–9 days in 
mice and appeared to be driven by a slower rate of elimi-
nation of PfHRP2 from the RBCs compared to plasma. 
While the longevity of PfHRP2 antigenaemia in the trans-
genic mouse model was considerably shorter than what is 
measured following a P. falciparum infection in humans, 
once-infected RBCs that were positive for the PfHRP2 
antigen were detected in mice. The fraction of these 
once-infected RBCs present over the days post-treatment 
was quantifiable in a small number of human patients 
and detected these once-infected RBCs post-treatment 
with artemether–lumefantrine and atovaquone–progua-
nil. While only 6 patients were investigated with most 
timepoints within a few days, this data could indicate that 
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pitting may not solely be driven by artesunate-based anti-
malarial regimens but could result from treatment with 
a variety of anti-malarials, and thus should be further 
explored. With the limited human samples included in 
this study, the PfHRP2 half-life in humans was not esti-
mated. It is important to note that time to clearance of 
half of PfHRP2 is different than half of total time to clear 
PfHRP2. Overall, these data suggest that erythrocyte pit-
ting in the spleen could be driving persistent protein in 
the RBCs and these once-infected RBCs are contributing 
to a longer duration of RDT positivity for PfHRP2 follow-
ing a successfully treated P. falciparum infection.
Additional files
Additional file 1: Table S1. Sequences of primers and fluorescent probes 
used to quantify PbPfHRP2 and P. falciparum infections.
Additional file 2: Figure S1. PCR verification that transgenic PbPfHRP2 
parasite carries the HRP2 gene. (A) PCR of 5′ and 3′ ends of the HRP2-2A-
GFP transgene from genomic DNA purified from whole blood from wild-
type P. berghei ANKA (lane 1) or PbPfHRP2 infected Swiss Webster mice 
(lane 2). (B) Integration PCR of genomic DNA purified from whole blood of 
wild-type P. berghei ANKA (lane 1 and 3) or PbPfHRP2 infected Swiss Web-
ster mice (lane 2 and 4). Lanes 1 and 2 show amplification upstream of the 
5′ integration site of 230p (forward) and the end of plasmid GFP (reverse). 
Lanes 3 and 4 show amplification at the start of the HRP2 gene (forward) 
and after the 3′ integration site of 230p (reverse).
Additional file 3: Figure S2. Presence of once-infected RBCs post-treat-
ment with different anti-malarials. Once-infected RBCs were detected in 
a patient that was qPCR negative for Pfs25 on day 12 post-treatment with 
artemether–lumefantrine (left) and another patient that was qPCR nega-
tive for Pfs25 on day 6 post-treatment with atovaquone–proguanil (right). 
Once-infected RBCs were defined as cells with positive PfHRP2 staining 
(red) but no DAPI staining.
Additional file 4: Figure S3. Investigation of the presence of once-
infected RBCs pre-treatment. iRBCs were isolated from a P. falciparum 
infected patient with a parasitaemia of 2.9% quantified by blood film prior 
to receiving treatment. No once-infected RBCs were observed prior to 
treatment. iRBCs were defined as cells with positive PfHRP2 (red) and DAPI 
staining (blue). Once-infected RBCs were defined as cells with positive 
PfHRP2 staining (red) but no DAPI staining (blue).
Additional file 5: Table S2. Distribution of PfHRP2 between naïve human 
or mouse RBCs and PfHRP2-containing plasma/sera incubated in vitro.
Additional file 6: Table S3. Distribution of rPfHRP2 between RBC and 
plasma fractions isolated from mice (n = 3) post-recombinant protein 
injection.
Additional file 7: Figure S4. Kinetics of recombinant PfHRP2 in plasma 
following protein injection. Female BALB/c mice (n = 3) were injected 
with rPfHRP2 protein. Plasma was collected at regular intervals post injec-
tion for quantification of rPfHRP2 plasma concentration. The protein half-
life in each mouse was calculated and averaged using a first-order decay 
equation model constrained at a plateau of Y = 0. Data are represented as 
mean ± SEM.
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